GH Research PLC has resolved the FDA clinical hold on its investigational new drug (IND) application for GH001, a treatment targeting resistant depression. This clearance allows the company to plan a pivotal phase 3 trial expected to begin in 2026. GH001 offers advantages such as a very short psychoactive phase of 11 minutes and fewer treatment visits compared to competitors like SPRAVATO. Positive early data also suggest potential for treating postpartum depression and Bipolar 2 Disorder, although financial risks remain a consideration for investors.
GH Research's GH001 drug development progress is the subject, with Pluang's Health sector market data providing context. Of 92 priced Health-sector US stocks on Pluang, 34 rose and 56 fell today. Notable movers include NBIX at USD 146.23 with a -3.69% change and 100% buy order activity, CNC at USD 65.11 down 2.95%, and BNTX at USD 96.06 down 2.64%. This data is as of Sep 20, 2026 20:31 WIB.
The Congressional Black Caucus (CBC) is strongly supporting legislation to regulate artificial intelligence, with nearly all of its 62 members ready to vote in favor of AI guardrails to ensure transparency and safety. CBC leaders emphasize the need t...
The US State Department has urged Americans outside the Middle East to reconsider travel due to the risk of rapid escalation in the Iran conflict. Iran insists the Strait of Hormuz will remain closed until its demands are met, including ending the na...
Toyosa, a Toyota dealer in Bolivia, has introduced Bitcoin as a payment option for purchasing Toyota vehicles, adding to its existing payment methods including bolivianos, U.S. dollars, and USDT stablecoins. This expansion follows Bolivia's 2024 regu...
Metaplanet has reduced its stock compensation plan by 41%, lowering the potential shares from 319.5 million to 188.2 million, yet VanEck criticizes the plan as still excessively dilutive. The Japanese company’s stock plan represents 14.7% of fully di...
MemeCore (M) has surged 35%, breaking past $1.70 to reach a two-month high of $1.77, driven by increased derivatives activity and strong trader interest. Despite this momentum, significant sell-side pressure is causing outflows in both Futures and Sp...
